

Yondelis[®] sales expanded by 70%

· The Group's net revenues increased 26% with respect to the same period last year.

· The Biopharmaceutical business reported 59% growth in sales with respect to September 2009, and consumer chemicals sales rose 6% in the same period.

· Zeltia Group maintains positive EBITDA in the first nine months of 2010.

Madrid, 28th October 2010: Group revenues totalled 120 million euro in the first nine months of 2010, i.e. an increase of 26.1% with respect to the same period last year (95.19 million euro).

Net sales in the Biopharmaceutical business amounted to 56.9 million euro (35.8 million euro in the first nine months of 2009), of which 51.8 million correspond to Yondelis sales (30.4 million euro in 9M09). Genómica's sales totalled 5.1 million euro.

The Consumer chemicals division reported sales of 62.2 million euro (58.6 million euro in 9M09). This division accounted for 51.8% of total group revenues in the first nine months of 2010 (61.5% in 9M09).

The Group maintained positive EBITDA of 2.7 million euro in 9M10, driven by steadily rising sales since the beginning of the year.

Net income attributable to the parent company improved 63% with respect to September 2009.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Noscira, a biotech firm focused on discovering and developing new drugs against Alzheimer's disease and other neurodegenerative diseases of the central nervous system; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing



(RNAi); and a chemical division comprising Zelnova and Xylazel, two profitable companies that are leaders in their respective market segments.

For more information +34 91 444 4500

This note is also available at Zeltia's web site: www.zeltia.com